JP2022511788A5 - - Google Patents

Info

Publication number
JP2022511788A5
JP2022511788A5 JP2021530816A JP2021530816A JP2022511788A5 JP 2022511788 A5 JP2022511788 A5 JP 2022511788A5 JP 2021530816 A JP2021530816 A JP 2021530816A JP 2021530816 A JP2021530816 A JP 2021530816A JP 2022511788 A5 JP2022511788 A5 JP 2022511788A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
individual
composition according
period
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021530816A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022511788A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/063413 external-priority patent/WO2020112880A1/en
Publication of JP2022511788A publication Critical patent/JP2022511788A/ja
Publication of JP2022511788A5 publication Critical patent/JP2022511788A5/ja
Priority to JP2024195531A priority Critical patent/JP2025024035A/ja
Withdrawn legal-status Critical Current

Links

JP2021530816A 2018-11-30 2019-11-26 S1p1受容体に関連する状態を治療する方法 Withdrawn JP2022511788A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024195531A JP2025024035A (ja) 2018-11-30 2024-11-08 S1p1受容体に関連する状態を治療する方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862773936P 2018-11-30 2018-11-30
US62/773,936 2018-11-30
US201962850464P 2019-05-20 2019-05-20
US62/850,464 2019-05-20
PCT/US2019/063413 WO2020112880A1 (en) 2018-11-30 2019-11-26 Methods of treating conditions related to the s1p1 receptor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024195531A Division JP2025024035A (ja) 2018-11-30 2024-11-08 S1p1受容体に関連する状態を治療する方法

Publications (2)

Publication Number Publication Date
JP2022511788A JP2022511788A (ja) 2022-02-01
JP2022511788A5 true JP2022511788A5 (cg-RX-API-DMAC7.html) 2022-12-05

Family

ID=68966033

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021530816A Withdrawn JP2022511788A (ja) 2018-11-30 2019-11-26 S1p1受容体に関連する状態を治療する方法
JP2024195531A Pending JP2025024035A (ja) 2018-11-30 2024-11-08 S1p1受容体に関連する状態を治療する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024195531A Pending JP2025024035A (ja) 2018-11-30 2024-11-08 S1p1受容体に関連する状態を治療する方法

Country Status (9)

Country Link
US (1) US20220023258A1 (cg-RX-API-DMAC7.html)
EP (1) EP3886841A1 (cg-RX-API-DMAC7.html)
JP (2) JP2022511788A (cg-RX-API-DMAC7.html)
KR (1) KR102824401B1 (cg-RX-API-DMAC7.html)
CN (2) CN118649163A (cg-RX-API-DMAC7.html)
AU (1) AU2019387212A1 (cg-RX-API-DMAC7.html)
CA (1) CA3120706A1 (cg-RX-API-DMAC7.html)
IL (1) IL283414A (cg-RX-API-DMAC7.html)
WO (1) WO2020112880A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2528894A1 (en) 2010-01-27 2012-12-05 Arena Pharmaceuticals, Inc. Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
CA3002540C (en) 2015-01-06 2023-11-07 Arena Pharmaceuticals, Inc. Use of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid for treating conditions related to the s1p1 receptor
JP6838744B2 (ja) 2015-06-22 2021-03-03 アリーナ ファーマシューティカルズ, インコーポレイテッド S1P1レセプター関連障害における使用のための(R)−2−(7−(4−シクロペンチル−3−(トリフルオロメチル)ベンジルオキシ)−1,2,3,4−テトラヒドロシクロペンタ[b]インドール−3−イル)酢酸(化合物1)の結晶性L−アルギニン塩
KR20190113955A (ko) 2017-02-16 2019-10-08 아레나 파마슈티칼스, 인크. 장-외 증상을 갖는 염증성 장질환의 치료를 위한 화합물 및 방법
CN110520124A (zh) 2017-02-16 2019-11-29 艾尼纳制药公司 用于治疗原发性胆汁性胆管炎的化合物和方法
JP7397011B2 (ja) 2018-06-06 2023-12-12 アリーナ ファーマシューティカルズ, インコーポレイテッド S1p1受容体に関連する状態を治療する方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104311472B9 (zh) * 2008-07-23 2020-03-17 艾尼纳制药公司 经取代的1,2,3,4-四氢环戊并[b]吲哚-3-基乙酸衍生物
EP2528894A1 (en) 2010-01-27 2012-12-05 Arena Pharmaceuticals, Inc. Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
WO2013116657A1 (en) * 2012-02-03 2013-08-08 Teva Pharmaceutical Industries Ltd. USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNFα THERAPY
RU2016147569A (ru) * 2014-05-09 2018-06-13 Ногра Фарма Лимитед Способы лечения воспалительного заболевания кишечника
CA3002540C (en) * 2015-01-06 2023-11-07 Arena Pharmaceuticals, Inc. Use of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid for treating conditions related to the s1p1 receptor
WO2017055611A2 (en) * 2015-09-30 2017-04-06 Nogra Pharma Limited Methods of using smad7 antisense oligonucleotides based on biomarker expression
CN110520124A (zh) * 2017-02-16 2019-11-29 艾尼纳制药公司 用于治疗原发性胆汁性胆管炎的化合物和方法

Similar Documents

Publication Publication Date Title
CN111132675B (zh) 胆汁淤积性瘙痒的治疗
JP2022516662A5 (cg-RX-API-DMAC7.html)
JP2505944B2 (ja) (S)―α―フルオロメチル―ヒスチジン及びそのエステルを含有するぜん息治療用医薬組成物
JP4938905B2 (ja) 選択的s1p1レセプターアゴニストの投与法
US20200323843A1 (en) Use of levocetirizine and montelukast in the treatment of viral infection caused by coronavirus
JP2015526458A5 (cg-RX-API-DMAC7.html)
JP2002542287A (ja) 医 薬
KR20200131816A (ko) 캡시드 조립 조절제 투약 요법
JP2023549849A5 (cg-RX-API-DMAC7.html)
US11883410B2 (en) Preventative and therapeutic agents for sarcopenia
CN115702143A (zh) 治疗系统性硬化症的方法
KR20170118830A (ko) 조현병의 치료를 위한 일로페리돈
JP2024084670A5 (cg-RX-API-DMAC7.html)
US11666587B2 (en) Veterinary composition comprising torasemide for the treatment of pulmonary edema associated with heart failure in domestic animals
JP4384435B2 (ja) くしゃみ抑制組成物
WO2019004465A1 (ja) ペマフィブラートを含有する医薬
JP2022550458A5 (cg-RX-API-DMAC7.html)
WO2005063253A1 (ja) アレルギー症状治療用医薬組成物
JP2010111667A (ja) フェキソフェナジン又はエバスチンを含有する鎮咳及び/又は去痰のための医薬組成物
JP2024539735A5 (cg-RX-API-DMAC7.html)
RU2021123406A (ru) Способы лечения состояний, связанных с рецептором s1p1
JP2020105081A (ja) 遅発相アレルギー反応抑制剤
JP2000290198A (ja) 鼻腔抵抗上昇等の抑制剤
HK1199815B (en) Levocetirizine and montelukast for the treatment of influenza and common cold
JP2003512293A (ja) 腸炎のための抗炎症薬を製造するためにアムトルメチングアシルの使用